Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MHRA

- PMLiVE

UCB’s $1.53bn generics sale falls through

Advent and Avista Capita back away from bid to acquire Kremers Urban due to unanticipated conflict in timing

National Institute for Health and Care Excellence NICE logo

Janssen sways NICE with Stelara discount

UK health watchdog set to recommend drug in psoriatic arthritis after agreeing patient access scheme

- PMLiVE

UCB partners with Daiichi to bring epilepsy drug to Japan

Companies partner on expanding market for Vimpat

- PMLiVE

UCB to sell its US generics business for $1.5bn

Advent International and Avista Capital Partners will take control of Kremers Urban Pharmaceuticals

- PMLiVE

Former NICE chair Sir Michael Rawlins to lead MHRA

He will take up his new role at the UK's medicines and devices regulator in December

Investing in the future of R&D

Roch Doliveux on UCB’s research plans and paying for innovation

- PMLiVE

Brain tumour vaccine is UK’s first ‘Promising Innovative Medicine’

Northwest Biotherapeutics’ DCVax-L gets UK version of ‘breakthrough’ status for use in cancer

Smartphone and social media adverse event project launched

The EU consortium's members will include UK regulator the MHRA

- PMLiVE

UCB wins new epilepsy indication for Vimpat in the US

FDA approves drug as monotherapy in patients with partial-onset seizures

- PMLiVE

MHRA launches online oral anticoagulation module

Aims to help healthcare professionals understand new blood clot treatments

- PMLiVE

Pfizer’s arthritis drug Enbrel widens its European licence

Gains new indication for early-stage inflammatory joint disease

- PMLiVE

UCB joins clinical trial data sharing portal

Follows GSK, Lilly, Roche and others in committing to transparency website

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links